The March 19, 2017 Summit brought patients and consumer advocates together with guideline developers, methodologists, and other stakeholders in the clinical guideline enterprise for the purpose of constructive dialogue and initiation of durable relationships between them.
At the March 9 and 10, 2017 Genetic Alliance Conference, Celiac Disease Foundation worked to determine best strategies to help grow our iCureCeliac® patient registry, and to encourage patients and their family members to engage in the research process to influence the future of celiac disease research toward treatments and a cure.
ImmusanT, a Cambridge, MA-based biotechnology company, has announced that Nexvax2®, an immunotherapy drug designed to protect celiac disease patients from gluten exposure, has successfully completed a Phase 1b clinical trial and is advancing to a Phase 2 trial. Currently, strict, lifetime adherence to a gluten-free diet is the only disease management protocol for celiac disease […]
In 1992, M.N. Marsh published a study aimed at measuring degrees of change seen in the structure of intestinal villi under microscopic scrutiny. Villi are finger-like projections which line the intestinal walls; their thin walls and large surface area are what allow for efficient absorption and digestion of nutrients. In patients with celiac disease, the […]
In addition to improving treatments and finding a cure for celiac disease, iCureCeliac® is helping researchers appreciate the realities of living with celiac disease, helping to influencing what they choose to research and why.
Celiac Disease Foundation (CDF) and the North American Society for the Study of Celiac Disease (NASSCD) are proud to announce Matthew Shale, MD, PhD as the recipient of the Young Investigator Award.
A study published November 3, 2016 in the Journal of Pediatric Gastroenterology, found that nearly 20% of children with celiac disease continued to show intestinal damage, despite adhering to a gluten-free diet for one year or more. The study, conducted by researchers at the Celiac Research Program at Harvard Medical School, sought to assess the accuracy […]
Researchers recently screened stored serum samples of over 6,000 individuals who participated in a National Health and Nutrition Examination Survey (NHANES III: 1988-1992). Each sample was tested for IgA anti-tTG and IgA endomysial antibodies, with the intention of determining whether a positive test correlated with increased risk of mortality in those age 50 and older. […]
On November 4, 2016, Celiac Disease Foundation was invited to present a live session of the Celiac Disease Patient Advocacy Program at the Center for Celiac Research and Treatment 20th Anniversary Celebration and Symposium at Massachusetts General Hospital. CDF CEO, Marilyn Geller, and Communications Manager, Talia Hassid, educated a packed room of people about patient-centered […]
A new study published online in The American Journal of Gastroenterology used fecal gluten immunogenic peptide (GIP) measurement to assess for patient compliance with the gluten-free diet. Gluten immunogenic peptides are pieces of gluten proteins that don’t get digested and produce immunotoxic reactions in patients with celiac disease. Traditionally, methods used to assess compliance ranged […]